Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT05695950 · ClinicalTrials.gov registry record · Phase 2

A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis

A Phase 2 study of Dermatomyositis, sponsored by Galapagos.

Active
Registry status
Phase 2
Development phase
40
Enrollment target
20
Study locations

NCT05695950 is a Phase 2 study of Dermatomyositis that is active but no longer recruiting, run by Galapagos. The registered enrollment target is 40 participants, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (92% lower). The trial reports 20 study locations across 8 states.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT05695950, a Phase 2 study of Dermatomyositis, is active but no longer recruiting, sponsored by Galapagos.

ACTIVE NOT RECRUITING
Registry status
Phase 2
Development phase
40 participants
Enrollment target
20
Study locations

Study Summary

The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM), followed by an open-label extension (OLE) period until Week 48.

Conditions Studied

Dermatomyositis

Interventions

  • DRUG Placebo
  • DRUG GLPG3667

Study Locations (20)

Other

  • Fundacion Respirar Consultorios Médicos Dr. Doreski - Buenos Aires
  • Hospital Cordoba - Córdoba
  • Hospital Italiano de La Plata - La Plata
  • Framingham Centro Medico - La Plata
  • Instituto Medico CER - Quilmes
  • UZ Leuven - Leuven
  • Enroll SpA - Santiago
  • BioMedica Research Group Psicomedica Clinical and Research Group - Santiago
  • Clinica de la Costa S.A.S - Barranquilla
  • Centro de Investigacion Medico Asistencial S.A.S - Barranquilla
  • Healthy Medical Center - Zipaquirá
  • Polyclinic Bonifarm - Zagreb

Florida

  • New Access Research and Medical Center - Kendall
  • Omega Research Orlando, LLC - Orlando

Arizona

  • HonorHealth Neurology - Scottsdale

California

  • Inland Rheumatology Clinical Trials, Inc. - Upland

Georgia

  • Augusta University - Augusta

Minnesota

  • St. Paul Rheumatology - Eagan

New York

  • Northwell Health, LLC PRIME - Lake Success

Pennsylvania

  • Altoona Center for Clinical Research, P.C. - Duncansville

Trial Details

FieldValue
Enrollment Target 40 participants
Start Date 2023-02-27
Est. Completion 2026-04
Phase Phase 2

Sponsor

Galapagos

7 total trials

Interested in This Trial?

Full Details on ClinicalTrials.gov ↗

What the Registry Record Tells You About NCT05695950

The ClinicalTrials.gov registry entry for NCT05695950 describes a study currently listed as active not recruiting, categorized as Phase 2. The registered enrollment target is 40 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 483-participant average among 19 other Dermatomyositis trials with a reported enrollment target (92% lower). The listed sponsor is Galapagos, which has 7 total studies on file at ClinicalTrials.gov.

The record links to 1 condition, with Dermatomyositis appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT05695950 reports 20 study locations spanning 8 distinct geographic areas - top geographies include Other, Florida, Arizona.

Frequently Asked Questions

What is clinical trial NCT05695950 about?

NCT05695950 is a clinical study titled "A Study Evaluating the Effects of GLPG3667 Given as Oral Treatment for up to 24 Weeks in Adults With Dermatomyositis". The purpose of this study is to evaluate the efficacy, safety, tolerability, pharmacokinetics (PK), and pharmacodynamics (PD) of orally administered GLPG3667 once daily for 24 weeks in adult participants with dermatomyositis (DM), followed by an open-label extension (OLE) period until Week 48.

What is the current status of trial NCT05695950?

This trial is currently active not recruiting. It is a Phase 2 study. The enrollment target is 40 participants. The study started on 2023-02-27. Estimated completion is 2026-04.

What conditions does trial NCT05695950 study?

This clinical trial studies the following conditions: Dermatomyositis.

What interventions are being tested in trial NCT05695950?

The interventions under investigation include: Placebo (DRUG), GLPG3667 (DRUG).

Who is sponsoring clinical trial NCT05695950?

This trial is sponsored by Galapagos, which has 7 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT05695950 being conducted?

This trial has 20 study locations across Arizona, California, Florida, Georgia, Minnesota. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Dermatomyositis

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Explore more on PlainTrial

Dermatomyositis

All registered trials for this condition

Arizona

All trials with a study site in Arizona

Recruiting now

Find trials open to new participants near you

Rankings

Top sponsors, conditions, and phases

Read our methodology - how this data is sourced, computed, and verified.

Related

Browse all → | Rankings →
Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.